Flexion meets primary endpoint in phase 3 trial of Zilretta in knee osteoarthritis
The endpoint was met at week 12 against placebo achieved p value of <0.0001. Zilretta also demonstrated significant analgesia against placebo at weeks 1 through 16. Flexion said
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.